Ghrelin - Asubio

Drug Profile

Ghrelin - Asubio

Alternative Names: SUN 11031

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asubio Pharma
  • Class Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Anorexia nervosa; Cachexia

Most Recent Events

  • 31 May 2015 No recent reports of development identified - Phase-II for Cachexia in Europe and USA (SC)
  • 31 May 2015 No recent reports of development identified - Phase-III for Anorexia nervosa in Japan (SC)
  • 15 Feb 2011 Ghrelin - Asubio is available for licensing as of 15 Feb 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top